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Six of the seven studies found a significant difference in 
serum IL-6 concentrations between women with 
endometriosis and women without. Three studies were able to 
identify severe endometriosis on the basis of higher levels of 
IL-6, indicating a positive relationship between concentration 
level and disease severity.
Abstract
Interleukin-6 (IL-6) is an inflammatory cytokine with a documented role in 
the pathophysiology of endometriosis. Many studies have suggested that 
it could serve as a biomarker to detect pathology. Seven studies that 
investigated serum concentrations of IL-6 in women with severe 
endometriosis were selected for review. The results of this analysis 
indicate that serum IL-6 is both higher in women with endometriosis when 
compared to controls, and also has a positive correlation with disease 
severity. This collectively indicates that IL-6 could be used a biomarker for 
the diagnosis, however, there is insufficient evidence to promote a clinical 
change in practice at this time.
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What is Endometriosis?
 Inflammatory disease defined by abnormal endometrial tissue growing 
outside the uterus.
 Clinically represented by chronic pelvic pain,  dyspareunia, 
dysmenorrhea and occasionally infertility.  
 Prevalence is estimated to be 10% in women of reproductive age.
How is Endometriosis Diagnosed?
 The only definitive diagnostic tool is direct visualization of the 
endometriotic lesions via laparoscopy.
 Laparoscopy is  an invasive modality that requires many resources, 
financially and medically.
 Finding an alternative to laparoscopy could remedy the diagnostic 
burden currently being carried by physicians and affected patients.
Introduction
A literature search was conducted via PubMed and 
ScienceDirect databases. Seven articles that evaluated the 
IL-6 concentrations in women with endometriosis were 
selected for review based on publication date, biomarkers 
evaluated and the type of specimen used. Each study’s 
validity was evaluated on the basis of control variable, sample 
size, and measurement modality. The results of each study 
were then analyzed and compared .
All but one of the studies demonstrated that IL-6 concentrations are able 
to differentiate between women with and women without endometriosis. 
Although the findings were not universal, they highly suggest that IL-6 
could play a significant role in the diagnosis of endometriosis when more 
studies can validate these results. Three of the studies showed a positive 
correlation between IL-6 levels and the severity of the endometriosis, 
suggesting that a future biomarker test could assist with staging of 
endometriosis as well. Although these results show promise for serum IL-6 
as a diagnostic tool for endometriosis, thorough analysis of the studies 
selected revealed several limitations listed below:
Limitations
 Inconsistent control for BMI 
 Small sample populations
 Use of different modalities to measure IL-6
Discussion 
Table 1. Comparison of Results  
Note: a p-value of less than 0.05 is considered statistically significant. Endo.=Endometriosis; the 
Control Group represents IL-6 concentrations in women without endometriosis. The Endo. Group 
represents IL-6 concentrations in those with confirmed pathology.
Results 
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Interleukin-6 as a Diagnostic Biomarker for Severe Endometriosis
All but one of the studies demonstrated that IL-6 concentrations are able 
to differentiate between women with and women without severe 
endometriosis. Although the findings were not universal, they highly 
suggest that IL-6 could have diagnostic value for this pathology in the 
future. Due to the relative inconsistency in results between these studies, 
more research needs to be conducted in order to further validate the 
relationship between IL-6 and endometriosis. Based on this meta-
analysis, there is insufficient evidence to promote serum IL-6 as a 
diagnostic alternative to laparoscopy in the diagnosis of severe 
endometriosis in women of reproductive age. Future research should aim 










Carmona et al 14± 1.6pg/ml 16.6± 1.51pg/ml <.01
Hadisaputra et al 1.08pg/ml 5.82pg/ml .029 






Othman et al 
.97pg/ml 4.41pg/ml <.001 




Socolov et al Not reported 11.83pg/ml .071





Graphic Courtesy of Complete Women Care*
